WHC is still in active development. Read this to understand our approach.
depiction of ROFVXGGUISEHAM-UHFFFAOYSA-N.svg
isomerdesign

URB-597

Check on isomerdesign

drugmap

Org-231295

Check on drugmap

wiki

URB597

Check on wiki

Data

InChI: InChI=1S/C20H22N2O3/c21-19(23)16-8-4-6-14(12-16)15-7-5-11-18(13-15)25-20(24)22-17-9-2-1-3-10-17/h4-8,11-13,17H,1-3,9-10H2,(H2,21,23)(H,22,24)

Synonyms: FAAH inhibitor, Schering-Plough/Kadmus/university of California,3'-Carbamoyl-[1,1'-biphenyl]-3-yl cyclohexylcarbamate, 3-(3-carbamoylphenyl)phenyl N-cyclohexylcarbamate, 546141-08-6,URB-597, KDS-1243, URB597,KDS-4103, Carbamic acid, N-cyclohexyl-, 3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl ester, PX47LB88FO, FAAH inhibitor, Merck & Co, URB 597, UNII-PX47LB88FO, KDS-4103, 3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate, 3'-Carbamoylbiphenyl-3-yl cyclohexylcarbamate, FAAH Inhibitor II, URB-597, CHEMBL184238, [3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate, Cyclohexyl-carbamic acid 3'-carbamoyl-biphenyl-3-yl ester

Estimated data

Solubility: -4.057 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: No (prediction using frontiersin.org)

Addictivity Prediction: 38.1% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.